PL4039675T3 - Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe - Google Patents

Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe

Info

Publication number
PL4039675T3
PL4039675T3 PL21211015.9T PL21211015T PL4039675T3 PL 4039675 T3 PL4039675 T3 PL 4039675T3 PL 21211015 T PL21211015 T PL 21211015T PL 4039675 T3 PL4039675 T3 PL 4039675T3
Authority
PL
Poland
Prior art keywords
phenyl
hydroxyacetylamine
methyl
compounds
phenyl compounds
Prior art date
Application number
PL21211015.9T
Other languages
English (en)
Inventor
Marta Maria CIFUENTES-GARCIA
Maria Cristina GARCIA-PAREDES
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL4039675T3 publication Critical patent/PL4039675T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL21211015.9T 2017-04-18 2018-04-11 Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe PL4039675T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382207 2017-04-18

Publications (1)

Publication Number Publication Date
PL4039675T3 true PL4039675T3 (pl) 2025-01-07

Family

ID=58606227

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18718570T PL3612519T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe
PL21211015.9T PL4039675T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18718570T PL3612519T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe

Country Status (30)

Country Link
US (2) US11655214B2 (pl)
EP (2) EP3612519B1 (pl)
JP (2) JP7110232B2 (pl)
KR (2) KR102575246B1 (pl)
CN (2) CN117510405A (pl)
AU (2) AU2018255191B2 (pl)
BR (1) BR112019021867A2 (pl)
CO (1) CO2019012767A2 (pl)
CR (1) CR20190519A (pl)
CY (1) CY1125150T1 (pl)
DK (2) DK4039675T3 (pl)
ES (2) ES2988739T3 (pl)
FI (1) FI4039675T3 (pl)
HR (2) HRP20220263T1 (pl)
HU (2) HUE068023T2 (pl)
IL (2) IL270005B (pl)
LT (2) LT4039675T (pl)
MX (2) MX389724B (pl)
MY (1) MY199442A (pl)
NZ (1) NZ758291A (pl)
PH (1) PH12019502363B1 (pl)
PL (2) PL3612519T3 (pl)
PT (2) PT4039675T (pl)
RS (2) RS65914B1 (pl)
SA (1) SA519410320B1 (pl)
SG (1) SG11201909680UA (pl)
SI (2) SI3612519T1 (pl)
SM (2) SMT202200100T1 (pl)
WO (1) WO2018194885A1 (pl)
ZA (1) ZA201906811B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3612519T1 (sl) * 2017-04-18 2022-04-29 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine
MX2020009922A (es) 2018-03-26 2020-10-14 Icahn School Med Mount Sinai Metodos de tratamiento del cancer residual minimo.
US12331054B2 (en) 2019-08-29 2025-06-17 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
WO2021041975A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
CN114585606A (zh) * 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
WO2021041976A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting indolinyl compounds
KR20220110744A (ko) 2019-11-06 2022-08-09 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法
JP2026513203A (ja) * 2023-03-30 2026-04-23 ハイバーセル，インコーポレイテッド （ｒ）－２－アミノ－５－（４－（２－（３，５－ジフルオロフェニル）－２－ヒドロキシアセトアミド）－２－メチルフェニル）－ｎ－イソプロピルニコチンアミドの結晶形態及びその使用方法
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
CA2484209C (en) * 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
DK1663978T3 (da) * 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
WO2005030933A2 (en) 2003-09-24 2005-04-07 Genera Doo Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
US8211919B2 (en) * 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
NZ600339A (en) 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
WO2010080992A1 (en) 2009-01-09 2010-07-15 The Trustees Of The University Of Pennsylvania Regulators of the interferon-alpha receptor 1 (ifnar1) chain of the interferon receptor
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
CN104619686A (zh) * 2012-08-23 2015-05-13 霍夫曼-拉罗奇有限公司 用于治疗癌症的新的苯基-吡啶/吡嗪酰胺
WO2014170706A1 (en) 2013-04-15 2014-10-23 Università Degli Studi Di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
ES2685661T3 (es) 2013-11-08 2018-10-10 Ono Pharmaceutical Co., Ltd. Derivado de pirrolopirimidina
EP3116877A1 (en) * 2014-03-11 2017-01-18 Glaxosmithkline Intellectual Property (No. 2) Limited Chemical compounds acting as perk inhibitors
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
KR102562866B1 (ko) 2014-11-14 2023-08-04 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
AU2016297754A1 (en) * 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
US10399988B2 (en) 2016-07-07 2019-09-03 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
AU2017300123A1 (en) 2016-07-20 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as PERK inhibitors
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
WO2018138358A1 (en) 2017-01-30 2018-08-02 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
SI3612519T1 (sl) 2017-04-18 2022-04-29 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine
WO2019099564A1 (en) 2017-11-14 2019-05-23 Children's Medical Center Corporation Novel imidazopyrimidine compounds and uses thereof
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
MX2020009922A (es) 2018-03-26 2020-10-14 Icahn School Med Mount Sinai Metodos de tratamiento del cancer residual minimo.
CA3104398A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020070053A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Also Published As

Publication number Publication date
AU2018255191B2 (en) 2022-04-21
LT3612519T (lt) 2022-03-25
SMT202200100T1 (it) 2022-03-21
CN117510405A (zh) 2024-02-06
MY199442A (en) 2023-10-28
EP3612519B1 (en) 2021-12-01
ES2988739T3 (es) 2024-11-21
RU2019136694A3 (pl) 2021-05-19
DK4039675T3 (da) 2024-09-02
SI3612519T1 (sl) 2022-04-29
AU2022206702B2 (en) 2024-04-11
JP2021517555A (ja) 2021-07-26
KR20190140966A (ko) 2019-12-20
MX2019012428A (es) 2022-01-28
IL288822A (en) 2022-02-01
CO2019012767A2 (es) 2020-04-01
JP2022141835A (ja) 2022-09-29
AU2022206702A1 (en) 2022-08-11
SA519410320B1 (ar) 2022-05-08
ZA201906811B (en) 2021-01-27
IL270005B (en) 2022-01-01
RS62933B1 (sr) 2022-03-31
PL3612519T3 (pl) 2022-05-02
MX2022001310A (es) 2022-03-02
US11655214B2 (en) 2023-05-23
JP7331212B2 (ja) 2023-08-22
JP7110232B2 (ja) 2022-08-01
MX389724B (es) 2025-03-20
AU2018255191A1 (en) 2019-11-07
BR112019021867A2 (pt) 2020-05-26
RS65914B1 (sr) 2024-10-31
KR20230129627A (ko) 2023-09-08
KR102575246B1 (ko) 2023-09-06
CN110831927A (zh) 2020-02-21
US20230373922A1 (en) 2023-11-23
ES2906847T3 (es) 2022-04-20
HUE068023T2 (hu) 2024-12-28
PT3612519T (pt) 2022-02-22
PH12019502363A1 (en) 2020-12-07
SMT202400357T1 (it) 2024-11-15
CY1125150T1 (el) 2023-06-09
DK3612519T3 (da) 2022-03-07
PT4039675T (pt) 2024-09-16
SI4039675T1 (sl) 2024-10-30
CA3060564A1 (en) 2018-10-25
EP4039675B1 (en) 2024-06-12
IL288822B2 (en) 2023-06-01
HUE057745T2 (hu) 2022-06-28
HRP20241188T1 (hr) 2024-12-06
US12590064B2 (en) 2026-03-31
RU2019136694A (ru) 2021-05-18
CR20190519A (es) 2020-03-06
WO2018194885A1 (en) 2018-10-25
HRP20220263T1 (hr) 2022-04-29
FI4039675T3 (fi) 2024-09-10
SG11201909680UA (en) 2019-11-28
LT4039675T (lt) 2024-10-10
EP3612519A1 (en) 2020-02-26
NZ758291A (en) 2025-11-28
CN110831927B (zh) 2023-07-14
US20210114985A1 (en) 2021-04-22
PH12019502363B1 (en) 2023-11-15
EP4039675A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3578560A4 (en) QUINAZOLINE COMPOUND
CL2018000524S1 (es) Golilla
EP3609871A4 (en) ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
EP3589248A4 (en) CRYOTHERAPIES
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3588580A4 (en) SCHOTTKY MOS TRENCH DIODE
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
DK3351526T3 (da) Diisopentylterephthalat
MA49750A (fr) Dihydrooxadiazinones
DK3568655T3 (da) Rekuperator
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
LT3464336T (lt) Junginiai
EP3721165C0 (en) MILITARY CHARGE
DK3612237T3 (da) Genterapi
EP3611402A4 (en) SERVO CYLINDER
EP3615471A4 (en) PLASMA PHOTOELECTRONIC IMMUNE SENSOR
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
DK3672941T3 (da) Pyridylpyridonforbindelser
HUE056928T2 (hu) Új vegyületek
DK3672962T3 (da) Morpholinylpyridonforbindelser
DK3510051T3 (da) Carboxylalkylchitosan
DK3676276T3 (da) Spirothietannukleosider
DK3395159T3 (da) Ballepresse